AcuCort (”AcuCort” eller ”Bolaget”) har publicerat Bolagets delårsrapport för det första kvartalet 2...
Alzecure har på senare tid stärkt profilen för bolagets ledande projekt, ACD856, genom att visa data...
Redeye's provides its initial take on Xbrane's Q1 report which confirmed a stronger than anticipated...
Kontraktstillverkaren Hanza levererade för tredje kvartalet i rad en stark rapport med förbättrade m...
Redeye notes that Paxman completes the offer to Dignitana.
Redeye comments on I-Tech’s Q1 figures that beat our estimates across the board, delivering growth o...
Redeye comments on Transtema’s Q1 report, showing strong organic growth in Sweden but a relatively s...
Redeye comments on Tessin’s Q1 results, which came in much weaker than expected.
Sales 2% higher than expected; 24% y-o-y FX adjusted But higher investments increased lead to miss o...
Redeye noted InfraCom's robust profitability, surpassing its EBITDA estimate by 21%.
Redeye comments on Truecaller’s Q1 2025 report, which was somewhat softer than expected.
Redeye comments on Xspray following an undramatic Q1 report.
Redeye updates on Invisio following weaker than expected Q1-results.
Redeye updates on G5 Entertainment post Q1-result which saw lower revenue than expected.
Redeye comments on BrightBid’s Q1 report, with numbers aligning with the preliminary figures.
Redeye updates its estimates and valuation following Cheffelo’s Q1 2025 report.
Redeye provides an in-depth take on AroCell’s Q1 report.
Investors House's Q1 report was solid, with Real Estate posting slightly better results than we esti...
Redeye strengthens its positive view of Avensia following a strong Q1 report, showing high growth an...
6% organic sales decline y-o-y Enmac shows progress with good order intake Adj.